Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

References

• Ohta A. A Metabolic immune checkpoint: Adenosine in tumor microenvironment. Front Immunol 2016; 7:109; PMID:27066002; https://doi.org/10.3389/fimmu.2016.00109
   PubMed Web of Science ®Google Scholar
• Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: New therapeutic approaches. Cancer Discov 2014; 4:879-88; PMID:25035124; https://doi.org/10.1158/2159-8290.CD-14-0341
   PubMed Web of Science ®Google Scholar
• Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol 2016; 29:7-16; PMID:27209048; https://doi.org/10.1016/j.coph.2016.04.001
   PubMed Web of Science ®Google Scholar
• Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. CD73-adenosine: A next-generation target in immuno-oncology. Immunotherapy 2016; 8:145-63; PMID:26808918; https://doi.org/10.2217/imt.15.106
   PubMed Web of Science ®Google Scholar
• Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011; 71:2892-900; PMID:21292811; https://doi.org/10.1158/0008-5472.CAN-10-4246
   PubMed Web of Science ®Google Scholar
• Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121:2371-82; PMID:21537079; https://doi.org/10.1172/JCI45559
   PubMed Web of Science ®Google Scholar
• Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, Smyth MJ. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012; 72:2190-6; PMID:22396496; https://doi.org/10.1158/0008-5472.CAN-12-0420
   PubMed Web of Science ®Google Scholar
• Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemela J, Laurila JP, Elima K, Jalkanen S, Salmi M. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011; 41:1231-41; PMID:21469131; https://doi.org/10.1002/eji.201041292
   PubMed Web of Science ®Google Scholar
• Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2010; 107:1547-52; PMID:20080644; https://doi.org/10.1073/pnas.0908801107
   PubMed Web of Science ®Google Scholar
• Terp MG, Olesen KA, Arnspang EC, Lund RR, Lagerholm BC, Ditzel HJ, Leth-Larsen R. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol 2013; 191:4165-73; PMID:24043904; https://doi.org/10.4049/jimmunol.1301274
   PubMed Web of Science ®Google Scholar
• Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MW et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 2016; 30:391-403; PMID:27622332; https://doi.org/10.1016/j.ccell.2016.06.025
   PubMed Web of Science ®Google Scholar
• Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer. Res. 2013; 19:5626-35; PMID:23983257; https://doi.org/10.1158/1078-0432.CCR-13-0545
   PubMed Web of Science ®Google Scholar
• Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, Dall'Acqua WF, Damschroder MM. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs 2016; 8:454-67; PMID:26854859; https://doi.org/10.1080/19420862.2016.1143182
   PubMed Web of Science ®Google Scholar
• Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology 2016; 5:e1208875; PMID:27622077; https://doi.org/10.1080/2162402X.2016.1208875
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; https://doi.org/10.1084/jem.20130579
   PubMed Web of Science ®Google Scholar
• Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 2011; 333:1030-4; PMID:21852502; https://doi.org/10.1126/science.1206954
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94:259-67; PMID:16404427; https://doi.org/10.1038/sj.bjc.6602930
   PubMed Web of Science ®Google Scholar
• Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl. Acad. Sci. USA 2013; 110:14711-6; PMID:23964122; https://doi.org/10.1073/pnas.1308209110
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; https://doi.org/10.1038/nri2206
   PubMed Web of Science ®Google Scholar
• Krasnova Y, Putz EM, Smyth MJ, Souza-Fonseca-Guimaraes F. Bench to bedside: NK cells and control of metastasis. Clin Immunol 2015; Oct 22. pii: S1521-6616(15)30050-4; PMID:26476139; https://doi.org/10.1016/j.clim.2015.10.001
   PubMed Web of Science ®Google Scholar
• Sadej R, Skladanowski AC. Dual, enzymatic and non-enzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol 2012; 59:647-52; PMID:23162807
   PubMed Web of Science ®Google Scholar
• Airas L, Hellman J, Salmi M, Bono P, Puurunen T, Smith DJ, Jalkanen S. CD73 is involved in lymphocyte binding to the endothelium: Characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J Exp Med 1995; 182:1603-8; PMID:7595232; https://doi.org/10.1084/jem.182.5.1603
   PubMed Web of Science ®Google Scholar
• Zhi X, Chen S, Zhou P, Shao Z, Wang L, Ou Z, Yin L. RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis 2007; 24:439-48; PMID:17587186; https://doi.org/10.1007/s10585-007-9081-y
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, Smith P, Ravetch JV. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. USA 2010; 107:19396-401; PMID:20974962; https://doi.org/10.1073/pnas.1014515107
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: Neutral no more. Nat Rev Cancer 2016; 16:431-46; PMID:27282249; https://doi.org/10.1038/nrc.2016.52
   PubMed Web of Science ®Google Scholar
• van Egmond M, Bakema JE. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol 2013; 23:190-9; PMID:23287459; https://doi.org/10.1016/j.semcancer.2012.12.002
   PubMed Web of Science ®Google Scholar
• Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309-14; PMID:9630891; https://doi.org/10.1038/nbt0396-309
   PubMed Web of Science ®Google Scholar